Targetable “Driver” Mutations in Non Small Cell Lung Cancer

Vijayalakshmi, R.

doi:10.1007/s13193-011-0108-0

Cited by 24 publications

(22 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer remains the leading cause of cancer-related mortality worldwide despite advances in the field of cancer therapeutics (2). Traditional treatment with empirically selected cytotoxic chemotherapeutic agents has provided small, but real survival benefits (2).…”

Section: Discussionmentioning

confidence: 99%

“…Traditional treatment with empirically selected cytotoxic chemotherapeutic agents has provided small, but real survival benefits (2). Moreover, cancer recurrence and subsequent resistance to chemotherapy remain problematic and the mechanisms are not clear.…”

Section: Discussionmentioning

confidence: 99%

“…Lung cancer is one of the most harmful malignant tumors to human health and life and its incidence is increasing every year, ranking first in large- and medium-sized cities in the incidence of malignant tumors (1,2). Two-thirds of patients are in the advanced stage when diagnosed with lung cancer and lose the opportunity for surgical treatment.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Synergy of Taxol and rhein lysinate associated with the downregulation of ERK activation in lung carcinoma cells

Zhen

Zhao

et al. 2013

Oncology Letters

View full text Add to dashboard Cite

In previous studies we observed that rhein lysinate (RHL), a salt of rhein and lysine that is easily dissolved in water, inhibited the growth of tumor cells in breast cancer, ovarian cancer, hepatocellular carcinoma and cervical cancer. The present study aimed to investigate the effects of RHL on H460 and A549 non-small cell lung cancer (NSCLC) cells using a combination of RHL and Taxol. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay was used to determine the growth inhibition effect of the drugs in the H460 and A549 cells. Cell apoptosis was analyzed by flow cytometry combined with fluorescein-isothiocyanate-Annexin V/propidium iodide (PI) staining. The expression levels of proteins were detected by western blotting. There was a significant reduction in the proliferation of the NSCLC cell lines treated with a combination of Taxol and RHL. The overall growth inhibition was directly correlated with apoptotic cell death. RHL potentiated Taxol-induced cell killing by reducing extracellular signal-regulated kinase (ERK) activity and increasing the levels of cleaved poly(ADP-ribose) polymerase (PARP) and caspase-3. Notably, the results for the Bcl-2 and NF-κB proteins also showed downregulation in the combined treatment group compared with the single-agent treatment and the untreated control groups. The present results showed that RHL potentiates the growth inhibition induced by Taxol in NSCLC cells and showed that this synergy may be associated with the downregulation of ERK activation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synergy of Taxol and rhein lysinate associated with the downregulation of ERK activation in lung carcinoma cells

Zhen

Zhao

et al. 2013

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…The distinct roles of the AKT isoforms in NSCLC are largely unknown, but AKT1 also downregulates PI3K pathway ( Fig. 1) [33][34][35][36][37].…”

Section: Akt1mentioning

confidence: 99%

A Review: Status of Genetic Modulated Nonsmall Cell Lung Cancer Targets and Treatment (Current Updates in Drugs for Non-Small Cell Lung Cancer Treatment)

Kumar

Purohit

Dagar

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Genetic modifications or mutations has been a bottleneck for the treatment of cancer; it is widely known to play a vital role in the progression of metastatic level/stage within the nonsmall cell lung cancer (NSCLC). The NSCLC of cancer is responsible for lung cancer lawsuits. In the various genetic mutations related study has been concluded with the various genes findings, which are named as the epidermal growth factor receptor, anaplastic lymphoma kinase, Kristen rat sarcoma virus, ROS proto-oncogene 1, human epidermal growth factor, B-RAF proto-oncogene, rearranged during Transfection, MET, Phosphatidyl 3-kinases CA, IGF-1R, NTRK1, FGFR1, and DDR2. The various research data supported this study. The involvement of the gene in the NSCLC patients made a paradigm shift in the drug discovery. The presence of one mutation in connection with some other could have an impact on NSCLC remedy.Utilizing this genotype-directed therapy for an advanced NSCLC has to turn out to be an appealing and efficacious treatment strategy. Here in the advancement of research, related genetic modulated targets and treatment have been discussed, particular genetic mutations help to find new updated interventions or medicinal drugs for the treatment of NSCLC. In there view, we have comprehensively arranged the mutation type and treatment with the status of NSCLC.

show abstract

“…Lung cancer is the leading cause of cancer-related mortality in both men and women worldwide [1]. More than 80% of lung cancer are non-small-cell lung cancer (NSCLC), which is comprised mostly of squamous cancers and adenocarcinomas [2,3]. According to survey of the American Cancer Society (ACS), lung cancer accounts for 28% of all male cancer deaths and 26% of all female cancer deaths in 2014 [4].…”

Section: Introductionmentioning

confidence: 99%

CHCHD2 is a potential prognostic factor for NSCLC and is associated with HIF-1a expression

Yin¹,

Xia

Sun

et al. 2020

BMC Pulm Med

View full text Add to dashboard Cite

Background: CHCHD2 was identified a novel cell migration-promoting gene, which could promote cell migration and altered cell adhesion when ectopically overexpressed in NIH3T3 fibroblasts, and it was identified as a protein necessary for OxPhos function as well. However, the clinic relevance of CHCHD2 expression in NSCLC remains unclear. Here we assumed that CHCHD2 expression would accompanies the expression of HIF-1α to response hypoxia in the occurrence of NSCLC. Methods: In order to verify this hypothesis, correlations among the expression levels of CHCHD2 and HIF-1α were detected and analyzed in 209 pair cases of NSCLC. The expression and location of these molecules were assessed using Immunohistochemistry, immunohistofluorescence, qRT-PCR and western blotting. The differences and correlations of the expression of these two molecules with clinical pathological characteristics in NSCLC were statistically analyzed using Wilcoxon (W) text, Mann-Whitney U, Kruskal-Wallis H and cross-table tests. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of the expression of CHCHD2 and HIF-1α on the patients' survival. Results: Data showed that CHCHD2 and HIF-1α expression were higher in NSCLC than in normal tissues (all P = 0.000). CHCHD2 expression was significantly related with smoking, tumor size, differentiation degree, TNM Stage, lymph metastasis (all P<0.05). The HIF-1α expression was significantly associated with smoking, tumor category, differentiation degree, TNM Stage, Lymph metastasis (all P<0.05). There was a marked correlation of CHCHD2 and HIF-1α expression with histological type, differentiation and lymph metastasis of NSCLC (all P<0.05, r s >0.3). Immunohistofluorescence showed that there were co-localization phenomenon in cytoplasm and nucleus between CHCHD2 and HIF-1α expression. NSCLC patients with higher CHCHD2 and HIF-1α expression had a significantly worse prognosis than those with lower CHCHD2 and HIF-1α expression (all P = 0.0001; log-rank test). The multivariate analysis indicated that CHCHD2 expression was an independent prognostic factor in NSCLC (hazard ratio [HR], 0.492, P = 0.001). Conclusion: Our results indicate that over-expression of CHCHD2 would promote the expression of HIF-1α to adapt the hypoxia microenviroment in NSCLC and CHCHD2 could serves as a prognostic biomarker in NSCLC.

show abstract

Targetable “Driver” Mutations in Non Small Cell Lung Cancer

Cited by 24 publications

References 75 publications

Synergy of Taxol and rhein lysinate associated with the downregulation of ERK activation in lung carcinoma cells

Synergy of Taxol and rhein lysinate associated with the downregulation of ERK activation in lung carcinoma cells

A Review: Status of Genetic Modulated Nonsmall Cell Lung Cancer Targets and Treatment (Current Updates in Drugs for Non-Small Cell Lung Cancer Treatment)

CHCHD2 is a potential prognostic factor for NSCLC and is associated with HIF-1a expression

Contact Info

Product

Resources

About